BS

Beat Steffen

Managing Director Novartis Venture Fund at Novartis

Basel, Basel

Invests in

Stages:

  • Min Investment:

    $5,000,000.00
  • Max Investment:

    $10,000,000.00
  • Target Investment:

    $7,500,000.00

Education

Work Experience

2006

  • Managing Director Novartis Venture Fund

    2021

  • Principal Novartis Venture Fund

    2015 - 2021

  • Global Franchise Head Critical Care ai

    2014 - 2015

  • General Manager Serelaxin

    2013 - 2014

  • Assistant to Head of Pharma Division

    2011 - 2013

  • Head Marketing General Medicines

    2009 - 2011

  • Associate Director Valturna

    2008 - 2009

  • Regional Director West CV Specialty Sales

    2006 - 2008

2021

  • Member Board of Directors

    2021

    SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research.

  • Chairman of the Board

    2020

    Rappta Therapeutics is a late preclinical stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecular glues that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).

  • Member Board of Directors

    2019

    Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

  • Member Board of Directors

    2022

    The UZH Life Sciences Fund (LSF) provides early financing for life sciences, biotech and med tech spin-offs whose business ideas are based on intellectual property resulting from research done at the University of Zurich. The aim is to accelerate the development process of such spin-offs in the early phase of their life cycle (when fund raising can be long and/or difficult), and thus accelerate the transfer of UZH research findings into practice, which ultimately benefits patients and the public at large.

  • Chairman of the Board

    2020 - 2022

  • Member Board of Directors

    2017 - 2020

2019 - 2020

  • Member Board of Directors

    2019 - 2020

    Binx Health is creating new categories of healthcare solutions that put on-demand testing where people need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer digital offerings, Binx is redefining "convenient care" for the modern consumer.

2017 - 2019

  • Member Board of Directors

    2017 - 2019

    A pioneering therapeutic approach harnessing the power of protein aggregation.

1999 - 2001

  • Senior Associate

    1999 - 2001

  • Resident in Cardiovascular Surgery

    1995 - 1998

    Cardiovascular Surgery